<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; GIPC</title>
	<atom:link href="http://www.tapanray.in/tag/gipc/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Dwindling Drug Innovation: Declining Image: Unchanged Business And Advocacy Models</title>
		<link>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models</link>
		<comments>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/#comments</comments>
		<pubDate>Mon, 20 Feb 2017 00:00:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2017]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Chasing]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Declining]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Dwinding]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[prices]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rainbows]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reputation]]></category>
		<category><![CDATA[research]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8099</guid>
		<description><![CDATA[A report of ‘The United States International Trade Commission (USITC)’ released on December 22, 2014 suggested, if tariffs and investment restrictions were fully eliminated, and standards of IP protection were made comparable to the U.S and Western European levels, American &#8230; <a href="http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/dwindling-drug-innovation-declining-image-unchanged-business-and-advocacy-models/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Is The Indian Patent Regime Weak?</title>
		<link>http://www.tapanray.in/is-the-indian-patent-regime-weak/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-indian-patent-regime-weak</link>
		<comments>http://www.tapanray.in/is-the-indian-patent-regime-weak/#comments</comments>
		<pubDate>Tue, 04 Mar 2014 09:45:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[energy]]></category>
		<category><![CDATA[Express]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regime weak]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[solar]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5049</guid>
		<description><![CDATA[“India misuses its own IP system to boost its domestic industries,” US Senator Orrin Hatch commented while introducing the 2014 report of the Global Intellectual Property Centre (GIPC) on ‘International Intellectual Property (IP) Index’. In this report, India featured at the &#8230; <a href="http://www.tapanray.in/is-the-indian-patent-regime-weak/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-indian-patent-regime-weak/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Big Pharma: Now A ‘Chink in Its Armor’?</title>
		<link>http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-now-a-chink-in-its-armour</link>
		<comments>http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/#comments</comments>
		<pubDate>Mon, 17 Feb 2014 00:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[&]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[Armour]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Chink]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Johnson]]></category>
		<category><![CDATA[lobbying]]></category>
		<category><![CDATA[MerckSerono]]></category>
		<category><![CDATA[NovoNordisk]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5000</guid>
		<description><![CDATA[Emerging trends bring to the fore a possible ‘Chink in the Armor’ of the ‘Big Pharma’, despite a number of recent belligerent moves. One such move I had deliberated in my earlier blog post. There I mentioned that 2014 report &#8230; <a href="http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-now-a-chink-in-its-armour/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“India is The Biggest Battlefield for Intellectual Property Rights”</title>
		<link>http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-is-the-biggest-battlefield-for-intellectual-property-rights</link>
		<comments>http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/#comments</comments>
		<pubDate>Wed, 05 Feb 2014 05:59:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[battlefield]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Biggest]]></category>
		<category><![CDATA[body]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[Consilium]]></category>
		<category><![CDATA[dispute]]></category>
		<category><![CDATA[GIPC]]></category>
		<category><![CDATA[Hatch]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Israel]]></category>
		<category><![CDATA[Orrin]]></category>
		<category><![CDATA[PAE]]></category>
		<category><![CDATA[patentability]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Pugatch]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[restoration]]></category>
		<category><![CDATA[Rights]]></category>
		<category><![CDATA[Senator]]></category>
		<category><![CDATA[settlement]]></category>
		<category><![CDATA[South]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[term]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4965</guid>
		<description><![CDATA[The US Senator Orrin Hatch reportedly made the above comment while introducing the 2014 report on ‘International Intellectual Property (IP) Index’, prepared by an Israel based consultancy firm &#8211; Pugatch Consilium for the Global Intellectual Property Centre (GIPC) of the &#8230; <a href="http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-is-the-biggest-battlefield-for-intellectual-property-rights/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
